China
· Delayed Price · Currency is CNY Gan & Lee Pharmaceuticals. Company Description
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China.
The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection.
It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices.
The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals.
in April 2005. Gan & Lee Pharmaceuticals.
was founded in 1998 and is headquartered in Beijing, the People’s Republic of China.
| Country | China |
| Founded | 1998 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 4,482 |
| CEO | Kai Du |
Contact Details
Address: No. 8, Nanfeng West 1st Street Beijing, 101109 China | |
| Phone | 86 10 8059 3699 |
| Website | ganlee.com |
Stock Details
| Ticker Symbol | 603087 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003ZH1 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kai Du | Chief Executive Officer |
| Cheng Sun | Chief Financial Officer |